Loading patent…
AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Medecine Et Innovation, Universite Paris Diderot—Paris 7, Centre National de la Recherche Scientifique (CNRS)
InventorsDaniel ZAGURY, Helene LE BUANEC, Sophie DUCHEZ, Valerie SCHIAVON, Armand BENSUSSAN
Estimating the term…
The present invention relates to therapeutic uses of ex vivo generated Foxp3+ regulatory T cells. The inventors showed the presence of Foxp3+ expressing T cells in tumor infiltrating lymphocytes (TILs) isolated from luminal-B breast cancer. The inventors performed an ex vivo generation and expansion of specific CD3+ TCRy8+ expressing Foxp3: CD3+ TCRy8+ T cells maintain their Foxp3 level and their suppressive activity, after a further 21-day-culture. They also showed that tumor Ag-specific CD3+ TCR Va24+ T cells maintain their ability to perform suppressive function in pro-inflammatory conditions. In particular, the present invention relates to immunotherapeutic uses of at least one of ex vivo generated Foxp3+regulatory T cells population selected among a MHCII restricted CD4+Foxp3+regulatory T cells population, a y8 Foxp3+regulatory T cells population and an invariant Foxp3+regulatory T cells population.
An immunogenic product, a pharmaceutical composition or a vaccine composition comprising at least one inactivated ex vivo generated Foxp3+ regulatory T cell population selected from the group consisting of a MHCII restricted CD4+ Foxp3+ regulatory T cell population, a γδ Foxp3+ regulatory T cell population and an invariant Foxp3+ regulatory T cell population.
(canceled)
Dependencies are inferred from the claim text.